Effect of Preoperative Curcumin in Breast Cancer Patients

University of Malaya30 enrolled

Overview

Effect of curcumin on modulation of immune and inflammatory parameters in pre-operative patients

Patients diagnosed with breast cancer will be supplemented with either curcumin or placebo for a minimum period of 2 weeks and may be extended up to 4 weeks prior to their surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

QUADRUPLE

Enrollment

Conditions

Breast Cancer

Interventions

CurcuminDIETARY_SUPPLEMENT

Natural compound, active ingredient of turmeric, in bi-daily dosing

PlaceboOTHER

Placebo tablets at bi-daily dosing

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with operable breast cancer * Life expectancy of at least 3 months * Adequate organ function * No allergy to curcumin * Provides consent to participate in trial and adhere to the study protocol Exclusion Criteria: * Receiving concomitant radiotherapy, hormonal, immune therapy or other investigational drugs * Uncontrolled concurrent illness * Patient of anti platelet medications * Pregnant / breast feeding * Patients who are unable or unwilling to take curcumin, herbal remedies, or non-prescription medications * Patients with bleeding tendency, bleeding disorders and abnormal bleeding/clotting profile

Locations (1)

University of Malaya Medical Center

Kuala Lumpur, Malaysia

Outcomes

Primary Outcomes

Tumour infiltrating lymphocytes (TILs)

Scoring as per recommendations by International Immuno-Oncology Biomarker Working Group

Time frame: For 2 to 4 weeks

Secondary Outcomes

FOXP3

Immunohistochemistry analysis

Time frame: For 2 to 4 weeks

CD68

Immunohistochemistry analysis

Time frame: For 2 to 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.